Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site rash
Clinical narrative: Hypersensitivity reaction; 3x3 inch red circle around the injection site; sore; itchy rash at the injection site; mild itchy rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Hypersensitivity reaction), VACCINATION SITE ERYTHEMA (3x3 inch red circle around the injection site) and VACCINATION SITE RASH (mild itchy rash at the injection site) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012L20A and 016M20A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Flu Vaccine in 2019. Past adverse reactions to the above products included Flu like symptoms with Flu Vaccine. Concurrent medical conditions included Wasp sting (Anaphylaxis) since 2020, Drug allergy (Nausea) since 2019, Drug allergy (Allergic reaction to mouth , gums swelling) since 2020, Anaphylaxis, Asthma, Hypersensitivity reaction, Hay fever and Urticaria. Concomitant products included ESTROGENS CONJUGATED (PREMARIN), SIMVASTATIN, LEVOTHYROXINE SODIUM (SYNTHROID), MULTIVITAMINS [VITAMINS NOS], VITAMIN C [ASCORBIC ACID], VITAMIN D [VITAMIN D NOS] and CALCIUM for an unknown indication.   On 11-Jan-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021 at 3:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Jan-2021, the patient experienced VACCINATION SITE RASH (mild itchy rash at the injection site). On 20-Jan-2021, the patient experienced HYPERSENSITIVITY (Hypersensitivity reaction) and VACCINATION SITE ERYTHEMA (3x3 inch red circle around the injection site). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency; CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) at a dose of 10 mg and ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE (PEPCID [ALUMINIUM HYDROXIDE GEL, DRIED;MAGNESIUM CARBONATE]) at a dose of 20 mg for 10 days. On 26-Jan-2021, VACCINATION SITE ERYTHEMA (3x3 inch red circle around the injection site) and VACCINATION SITE RASH (mild itchy rash at the injection site) had resolved. On 30-Jan-2021, HYPERSENSITIVITY (Hypersensitivity reaction) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medications included triamcinolone Acetonide Cream (21-Jan-2021 To 31-Jan-2021)   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: Updated patient info: address, race/ethnicity, and not pregnant. Updated info on 1st dose: arm, lot number, and time. Added conmeds, case became medically confirmed (patient sought medical care), patient got treatment from provider, and changed event outcome from 1st dose. On 18-Jun-2021: Follow up information was received on 18-Jun-2021 included patient medical history, allergic conditions, concomitant and treatment medication, events and outcome of the event.